Le Lézard
Classified in: Health
Subjects: PDT, BFA

SEPTEMBER IS NATIONAL CHRONIC PAIN MONTH AND THE OPIOID CRISIS IS IN FULL BLOOM. HOUSTON DERMATOLOGIST AND PHARMACIST HAS DEVELOPED A GROUNDBREAKING NEW CLASS OF TOPICAL PHARMACEUTICALS FOR PAIN THAT WILL NOT ADD TO THE CRISIS!


Moore Relief Dermaceuticals contain natural cosmetic ingredients that do not require OTC or prescription regulation.

The products have been launched and are available for purchase on www.moorerelief.com and Amazon.com.

HOUSTON, Sept. 28, 2022 /PRNewswire/ -- Dr. Milton D. Moore, a leading dermatologist and founder & CEO of Moore Unique Skin Care, LLC and Moore Unique Dermatology, today announced a new innovative product under the brand name Moore Relief Dermaceuticals: Moore Relief Pain Discomfort Lotion.

The opioid crisis is in full bloom - there is a new class of topical pharmaceuticals for pain that Moore Relief Dermaceuticals has available at www.moorerelief.com

The findings of Dr. Moore's clinical research in the development of this product were published in a recent article in the Journal of Dermatology Research (peer reviewed). Dr. Jack Alpert, a leading Houston Neurologist, has used the pain lotion in his practice and found the relief he obtained from the pain lotion was the best result he ever obtained in treating his patients in all his 25 years of practice by a large margin.

Listen to renowned Neurologist Dr. Jack Alpert, MD has to say about Moore Relief Pain & Discomfort Lotion:
Click here for video: Dr. Jack Alpert, MD Testimonial

Dr. Moore has seen an increase of patients who were depending upon opioids to help relieve their pain. Some of those patients chose to forego opioids and switch to non-opioid products.

In clinical research tests, Dr. Moore's patients applied the Moore Relief Pain Discomfort Lotion topically to areas in which they experienced recurring pain from carpal tunnel syndrome, sciatica, back, knee, fibromyalgia, and diabetic neuropathy. All the patients reported apparent relief of 75 to 100 percent in 1 to 5 minutes, and the relief lasted from 7-24 hours   

Moore Relief Dermaceuticals products are formulated with moisturizing and anti-inflammatory agents such as aloe vera, extracts of algae, argan oil as well as other natural ingredients. These products use Dr. Moore's patented transdermal delivery system, which enables the active ingredients to be absorbed by the skin quickly.

About Dr. Milton D. Moore
Dr. Milton Moore a pharmacist and dermatologist specializes in all types of dermatological products for 25 years. To review products and patient testimonials, visit WWW.MOORERELIEF.COM or WWW.MOOREUNIQUE.COM

Media Contact:
Taylor Walton
[email protected]
713-476-1726 or 713-741-9422

 

SOURCE Moore Relief Dermaceuticals LLC


These press releases may also interest you

at 06:30
The global microscopy market is poised for significant growth, expected to reach USD 10.6 billion by 2029 from USD 8.1 billion in 2024, growing at a CAGR of 5.4%. Key drivers include rising cases of chronic diseases necessitating effective...

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...



News published on and distributed by: